Skip to main content
S&P 5007,664.36+0.53%DOW52,429.15+0.41%NASDAQ26,073.85+0.46%BTC$79,611.00-0.87%ETH$2,302.24-1.37%GOLD$4,014.40+0.16%OIL$101.42-1.79%
Smart Investors Daily
SID Premium
PL

NASDAQ · PLRX

Pliant Therapeutics, Inc.

Healthcare · Biotechnology

$0.86

Down-$0.00 (-0.20%)

Updated Oct 26, 2026, 12:56 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
80.8M
P/E ratio
-0.46
Dividend yield
0.00%
52-week range
$0.83 – $1.95
Volume
446.82K
Avg. volume
1.08M

Price performance · PLRX

PLRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

PLRX closed at $0.86 after 20 trading sessions, down 20.04% for the selected period.

Last close
$0.86
Period change
-20.04%
Period low
$0.86
Period high
$1.08
Daily close
View OHLC price history
PLRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$0.87$0.879$0.831$0.8636446.82K
Oct 22, 2026$0.90$0.90$0.851$0.8653289.8K
Oct 21, 2026$0.9271$0.928$0.88$0.8858340.62K
Oct 20, 2026$0.9026$0.94$0.8963$0.9124319.69K
Oct 19, 2026$0.9127$0.928$0.875$0.8987292.31K
Oct 16, 2026$0.97$0.985$0.89$0.8999582.72K
Oct 15, 2026$0.90$0.9724$0.90$0.9724481.35K
Oct 14, 2026$0.961$0.9773$0.8838$0.8839988.88K
Oct 13, 2026$0.9826$0.9976$0.961$0.968284.64K
Oct 12, 2026$1.03$1.03$0.986$0.986272.19K
Oct 9, 2026$0.99$1.03$0.986$1.02288.53K
Oct 8, 2026$1.00$1.034$0.981$1.00568.05K
Oct 7, 2026$1.03$1.03$0.97$0.99756.5K
Oct 6, 2026$1.04$1.04$1.01$1.03276.39K
Oct 5, 2026$1.04$1.054$1.02$1.03295.62K
Oct 2, 2026$1.06$1.065$1.03$1.035402.81K
Oct 1, 2026$1.10$1.10$1.05$1.05379.55K
Sep 30, 2026$1.09$1.09$1.07$1.08238.68K
Sep 29, 2026$1.09$1.12$1.08$1.08214.5K
Sep 28, 2026$1.08$1.10$1.0709$1.08349.13K

Latest PLRX news

The latest Smart Investors Daily articles mentioning PLRX.

Stock researchCompany · Overview

PLRX research

Overview

Company profile and research snapshot.

Company profile

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$31.14
Implied upside
—
Analysts
—
PLRX recent ratings
DateFirmRatingTarget
Mar 13, 2026Canaccord GenuityHold—
Mar 12, 2026Piper SandlerOverweight—
Nov 7, 2025RBC CapitalSector Perform—
Oct 10, 2025JP MorganUnderweight—
Aug 8, 2025Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)

Craig D. Blanchette, Ph.D. Dr. Blanchette is a recognized leader in RNAi drug discovery and development was appointed Senior Vice President, Research (siRNA) of Pliant Therapeutics. Recognized leader in RNAi drug discovery with track record of advancing novel delivery platforms and therapeutics to drive Company’s integrin-mediated delivery platform SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focus

Yahoo · Oct 19, 2026

Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026

Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026. Poster Presentation Title: Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual αvβ8/αvβ1

Yahoo · Sep 30, 2026

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By